EAN 2026: Effective Markers for Detecting Relapse Activity and Long-Term Progression in MS

Disease progression in MS is a challenge to predict. In this MEDtalk from EHA 2026, Maximilian Einsiedler explains whether serum levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels can shed light on the risk of progression and the effect of disease-modifying therapy (DMT).